GR3021705T3 - Purified ciliary neurotrophic factor - Google Patents

Purified ciliary neurotrophic factor

Info

Publication number
GR3021705T3
GR3021705T3 GR960403098T GR960403098T GR3021705T3 GR 3021705 T3 GR3021705 T3 GR 3021705T3 GR 960403098 T GR960403098 T GR 960403098T GR 960403098 T GR960403098 T GR 960403098T GR 3021705 T3 GR3021705 T3 GR 3021705T3
Authority
GR
Greece
Prior art keywords
neurotrophic factor
ciliary neurotrophic
purified
purified ciliary
factor
Prior art date
Application number
GR960403098T
Other languages
English (en)
Inventor
Franklin D Collins
Leu-Fen Lin
Drzislav Mismer
Christine Ko
Original Assignee
Amgen Boulder Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/293,851 external-priority patent/US5011914A/en
Priority claimed from US07/404,533 external-priority patent/US4997929A/en
Application filed by Amgen Boulder Inc filed Critical Amgen Boulder Inc
Publication of GR3021705T3 publication Critical patent/GR3021705T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
GR960403098T 1989-01-05 1996-11-20 Purified ciliary neurotrophic factor GR3021705T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/293,851 US5011914A (en) 1989-01-05 1989-01-05 Purified ciliary neurotrophic factor
US07/404,533 US4997929A (en) 1989-01-05 1989-09-08 Purified ciliary neurotrophic factor
US07/458,564 US5141856A (en) 1989-01-05 1989-12-28 Expression of purified ciliary neurotrophic factor

Publications (1)

Publication Number Publication Date
GR3021705T3 true GR3021705T3 (en) 1997-02-28

Family

ID=27404236

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960403098T GR3021705T3 (en) 1989-01-05 1996-11-20 Purified ciliary neurotrophic factor

Country Status (21)

Country Link
US (2) US5141856A (el)
EP (1) EP0385060B1 (el)
JP (2) JPH0768270B2 (el)
KR (1) KR930012105B1 (el)
AU (1) AU7032496A (el)
BR (1) BR9006996A (el)
CH (1) CH681426A5 (el)
DD (1) DD299318A5 (el)
DE (1) DE4090006C2 (el)
DK (1) DK131391A (el)
ES (1) ES2091768T3 (el)
FI (1) FI104375B (el)
GB (1) GB2246132B (el)
GR (1) GR3021705T3 (el)
HU (2) HUT58792A (el)
IE (1) IE81151B1 (el)
IL (1) IL92958A (el)
NL (1) NL9020024A (el)
NZ (1) NZ231985A (el)
SE (1) SE513358C2 (el)
WO (1) WO1990007341A1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5328988A (en) * 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US5141856A (en) * 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
IE903130A1 (en) 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
NO911025L (no) * 1990-03-14 1991-09-16 Fidia Spa Fremgangsmaate til isolering og ekspresjon av human ciliarneuronotropisk faktor ved rekombinant dna-teknikk.
US6511823B1 (en) * 1990-08-20 2003-01-28 American Cyanamid Corporation Heparin binding neurotrophic factor gene sequence
IT1247150B (it) * 1991-01-21 1994-12-12 Fidia Spa Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.
US5593857A (en) * 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
CA2123234A1 (en) * 1991-11-11 1993-05-27 Lanfranco Callegaro Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor
US5360740A (en) * 1992-07-02 1994-11-01 Regeneron Pharmaceuticals, Inc. Assay system for degenerative muscle disease
ZA94608B (en) * 1993-01-29 1994-09-15 Regeneron Pharma Use of ciliary neurotrophic factor in a method of treating a neurological disorder
DK0632008T3 (da) * 1993-06-01 1998-09-23 Ono Pharmaceutical Co Pentansyrederivater
AU1847695A (en) * 1994-02-22 1995-09-04 Syntex-Synergen Neuroscience Joint Venture, The Pharmaceutical formulations of cntf
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US7258983B2 (en) * 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
DK0755446T3 (da) * 1994-04-25 2007-01-29 Genentech Inc Cardiotrophin og anvendelser deraf
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6743628B1 (en) 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
US6222022B1 (en) 1996-03-14 2001-04-24 Washington University Persephin and related growth factors
US6716600B1 (en) * 1996-03-14 2004-04-06 Washington University Persephin and related growth factors
NZ329482A (en) 1996-03-14 2000-05-26 Univ Washington A growth factor persephin related to the GDNF/neurturin family of growth factors Methods of treating conditions related to persephin deficiency detecting gene alterations and identifying other members of the family are included
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
IT1288388B1 (it) * 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6689573B1 (en) * 1999-05-24 2004-02-10 New England Biolabs, Inc. Method for screening restriction endonucleases
WO2001078789A2 (en) 2000-04-14 2001-10-25 The Uab Research Foundation Poliovirus replicons encoding therapeutic agents and uses thereof
US20050064555A1 (en) * 2003-07-09 2005-03-24 Xencor, Inc. Ciliary neurotrophic factor variants
US20100143500A1 (en) * 2006-10-31 2010-06-10 The Ohio State University Research Foundation Methods and Compositions for Inhibiting GSK-3 In Glial Cell Related Disorders
EP2646007B1 (en) 2010-12-02 2016-12-21 Neurotech USA, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
CA2986769A1 (en) 2015-05-27 2016-12-01 Neurotech Usa, Inc. Use of encapsulated cell therapy for treatment of ophthalmic disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US570651A (en) * 1896-11-03 Motor-driven fan
US293851A (en) * 1884-02-19 de castro
US408172A (en) * 1889-07-30 Steam-boiler house
US404533A (en) * 1889-06-04 Signments
US429517A (en) * 1890-06-03 Packing-box
US458564A (en) * 1891-09-01 Ring-gage
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5028622A (en) * 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5011914A (en) * 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US5141856A (en) * 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
EP0463082A1 (en) * 1989-03-15 1992-01-02 The Regents Of The University Of California Purified ciliary neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
FI912358A7 (fi) * 1989-09-15 1991-05-15 Regeneron Pharma Silmäkuopan takaosan hermosolmun neurotrofinen tekijä
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors

Also Published As

Publication number Publication date
HUT58792A (en) 1992-03-30
KR930012105B1 (ko) 1993-12-24
IL92958A (en) 1997-09-30
BR9006996A (pt) 1991-11-12
NZ231985A (en) 1992-12-23
NL9020024A (nl) 1991-10-01
ES2091768T3 (es) 1996-11-16
DD299318A5 (de) 1992-04-09
IL92958A0 (en) 1990-09-17
US5780600A (en) 1998-07-14
EP0385060B1 (en) 1996-08-28
DE4090006C2 (de) 1996-09-19
GB2246132A (en) 1992-01-22
EP0385060A2 (en) 1990-09-05
KR910700068A (ko) 1991-03-13
SE9102079D0 (sv) 1991-07-03
IE900020L (en) 1990-07-05
AU4838190A (en) 1990-08-01
EP0385060A3 (en) 1991-04-03
JPH04502916A (ja) 1992-05-28
GB2246132B (en) 1993-09-15
GB9113704D0 (en) 1991-08-21
JPH1129598A (ja) 1999-02-02
GB2246132A8 (en) 2001-05-22
FI913251A0 (fi) 1991-07-04
DK131391A (da) 1991-09-05
JPH0768270B2 (ja) 1995-07-26
SE513358C2 (sv) 2000-08-28
SE9102079L (sv) 1991-07-03
FI104375B (fi) 2000-01-14
HU211933A9 (en) 1996-01-29
CH681426A5 (el) 1993-03-31
AU7032496A (en) 1997-01-16
IE81151B1 (en) 2000-05-03
US5141856A (en) 1992-08-25
DK131391D0 (da) 1991-07-05
AU642858B2 (en) 1993-11-04
WO1990007341A1 (en) 1990-07-12

Similar Documents

Publication Publication Date Title
GB2246132A8 (en) Purified ciliary neurotrophic factor
ZA9081B (en) Purified ciliary neurotrophic factor
LTIP1546A (en) Cerebral neurothropic factor
AU108998S (en) Lamp
GB2228528B (en) Stay
EP0423928A3 (en) Multi-ferrule structure
IL94829A0 (en) Indenoindoles i
GB9027564D0 (en) Microlaminated structure
IL95678A0 (en) Novel alkanophenones
GB2239467B (en) Support structure
GB2227788B (en) Stay
ZA907303B (en) Ciliary neurotrophic factor
GB9003300D0 (en) Can ends
HUT60012A (en) Height-limiting structure
IL83686A0 (en) Neurotrophic factor
IL95679A0 (en) Novel alkanophenones
NO964837D0 (no) Renset ciliær neurotrofisk faktor
GB8927241D0 (en) Kerbing structure
HUT60011A (en) Height-limiting structure
HUT56427A (en) Door-case structure
CA63830S (en) Support
IE894206L (en) Novel immunoglobulins
CS456188A2 (en) Profile inductor
AU111962S (en) Profile
GB8924818D0 (en) Support structure